Research Study

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Principal Investigator 
Alissa Wright

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT02927067
Status 
Recruiting
Study Start/End 
Apr 13, 2018 to Aug 1, 2021
Locations 
Vancouver General Hospital
Name/Title 
Claudia Piechnik, Research Assistant
Phone 
604-875-4111 ext.22958
Purpose of Study 

The purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.